This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Peripheral artery disease is an under-diagnosed, chronic and progressive disease caused by narrowing of the arteries outside of the heart and brain. Previously called peripheral vascular disease (PVD), PAD is now recommended to describe atherosclerotic disease affecting the lower or upper extremity arteries (Creager, et al., 2008). Symptoms of PAD are often variable or not present; therefore, diagnosis is often missed. Risk factors are the same as coronary artery disease (CAD), with tobacco use and diabetes mellitus (DM) having the most significant impact. Primarily the result of atherosclerosis, PAD manifests with chronic, insufficient tissue perfusion and ischemia, potentially complicated by a thrombotic or embolic event. The ACC/AHA classifies the disease in 4 categories: asymptomatic, claudication, critical limb ischemia (CLI), and acute limb ischemia (ALI) (Hirsch, 2006). Current guidelines suggest the use of resting ankle-brachial index (ABI) for diagnostic confirmation of patients with suspected or known lower extremity PAD, defined by an ABI < 0.90 (Center for Disease Control: Peripheral Arterial Disease Fact Sheet, 2010). Screening patients for PAD is reserved for those with exertional leg symptoms, a non-healing leg ulcer, patients greater than age 65, greater than age 50 with a history of smoking or DM, or less than 50 with DM and another risk factor (Hirsch, 2006). Routine screening for asymptomatic PAD, however is not recommended. Early diagnosis of PAD can help prevent progression and complications both peripherally and systemically. Without general population screening, the early diagnosis of asymptomatic PAD depends on the ability of the health care provider to evaluate risk, take a detailed history, and pick up on subtle physical exam findings. If diagnosed in early stages, lifestyle and risk factor modification, medications, and vascular procedures can be utilized to decrease morbidity and mortality.
PAD currently affects nearly 12% (8 million) of Americans, beginning at the age of 40. The prevalence increases with age: 1-2% in 40-49 year olds, 3-5% in 50-59 year olds, 5-6% in 60-69 year olds, 9-11% in 70-79 year olds, and 21-26% in >80 year olds (CDC, 2010). As people with chronic illness are living longer, the prevalence of PAD will likely increase in the future. Men are affected more than women in the younger population, but the incidence is nearly equal in the older population. There is also a 2.4-fold prevalence increase in African Americans compared to the non-Hispanic white population (Criqui et al., 2005). The prevalence for PAD in the US is similar to that of other developed countries (Paraskevas, 2011). In the presence of CAD or cerebrovascular disease (CVD), there is a 50 to 75% chance that PAD is also present, as atherosclerosis is a systemic disorder. Oftentimes, in the presence of both PAD and CVD, one disease might remain silent because the other limits exercise by claudication or angina.
The most common cause of PAD is atherosclerosis. Atherosclerosis is an inflammatory disease that is a result of a chain of step-like insults to the arteries. The disease process is initiated by endothelial injury and dysfunction, leading to a fatty streak, causing a fibrotic plaque, and potentially ending with a complicated lesion.
The initial injury to the endothelial cells, the inner lining of the artery wall, can be caused by many of the risk factors seen in PAD: smoking, hypertension, diabetes, hyperhomocystinemia, dyslipidemia, and increased C-reactive protein levels. Additionally, autoimmune phenomena, vessel shear, and increases in fibrinogen levels can cause endothelial damage. An inflammatory mediated cascade is initiated at the site of injury, resulting in an accumulation of macrophages. After adherence to the vessel wall, the macrophages release free radicals and then begin to migrate through the endothelial surface into media of the vessel. Lipid localization and accumulation also occurs at the site of endothelial injury, leading to free radical oxidation of low-density lipoproteins (LDL). Hypertension, smoking and diabetes also increase oxidation of LDL. Oxidized LDL initiates smooth muscle proliferation as well as abnormal vasoconstriction. Macrophages then engulf the oxidized LDL and penetrate the intima of the vessel, creating what is known as a foam cell. The accumulation of many foam cells in the intimal layer of the artery creates a fatty streak, the earliest visible lesion of atherosclerosis. Over time, smooth muscle cells proliferate, produce collagen, migrate over the fatty streak, and evolve into a fibrous plaque, the hallmark of established atherosclerosis. Ultimately the lesion may evolve to contain large amounts of lipid; if it becomes unstable, denudation of overlying endothelium or plaque rupture then initiates the coagulation cascade and can result in thrombotic occlusion of platelets and fibrin in the overlying artery.
The lesions of atherosclerosis are often segmental and localized to large and medium-sized vessels. They are typically seen at arterial branch points, which are sites of increased turbulence, altered shear stress, and intimal injury. Typically located in multiple sites, stenosis and occlusion are most often seen in the abdominal aorta and iliac arteries (30% of symptomatic patients), the femoral and popliteal arteries (80-90% of patients), and the tibial and peroneal arteries (40-50% of patients) ( Bartholomew & Olin, 2006).
PAD has three primary systems of classification. The Fontaine Classification and the Rutherford Classification are used to grade the severity of clinical symptoms in patients (see table 1). Even with a similar extent and level of disease progression, presence of and severity of symptoms may vary from one person to another. Both the Rutherford and the Fontaine Classifications are used more routinely in research settings and are utilized less in clinical practice. However, as the¿½2005 ACC/AHA guidelines point out, a way of standardized communication between clinicians is important, and it is suggested to describe a patient¿½s status as 1) Asymptomatic, 2) Claudication, 3) Critical Limb Ischemia, or 4) Acute Limb Ischemia.
Asymptomatic PAD is simply described by the absence of claudication symptoms of the legs.
The term claudication is derived from the Latin verb ¿½claudicare¿½, meaning to limp (Norgren et al., 2007). Claudication is one of the most common manifestations of PAD and is defined by reproducible, ischemic muscle pain. Claudication occurs during physical activity secondary to inadequate blood flow and is relieved after a short rest. In order to be classified as claudication, the pain must be exertional, reproducible, and relieved within 10 minutes of rest (Creager et al., 2012). Atypical leg pain also falls amongst this class in the absence of symptoms of CLI.
Critical limb ischemia
CLI describes patients with chronic, ischemic rest pain, ulcers or gangrene, which can be attributed to arterial occlusive disease (Norgren et al., 2007). CLI implies chronicity, distinguishing it from acute limb ischemia.
Acute limb ischemia
ALI is defined by a sudden decrease in limb perfusion, which poses a potential threat to limb viability. Presentation is typically up to 2 weeks following the acute event. (Norgren et al., 2007).
5. Risk factors
Most risk factors for PAD are the same as those of CVD: older age, hypertension, diabetes, dyslipidemia, tobacco use, a family history of atherosclerosis, obesity, sedentary lifestyle, and high homocysteine or C-reactive protein levels. Of the risk factors, diabetes and smoking should be of high focus to the clinician, as they are the strongest modifiable risk factors.
Smoking has been shown to enhance endothelial dysfunction and alter both lipid metabolism and anticoagulation (Lu & Creager, 2004). An interesting case-control study (Cole et al., 1993) estimated that 76% of PAD is attributable to smoking, with a 7-fold increase in previous smokers and 16-fold increase in current smokers. Smoking cessation is associated with a rapid decline in the incidence of claudication, which equates to that in non-smokers after 1 year of stopping (Tendera, 2011).
The other strongest risk factor for PAD is diabetes, with a proportionate correlation of incidence and prevalence with the duration the patient has been diabetic. There is a 2-4 fold increased risk for PAD with diabetes and approximately 30% of PAD patients in primary care suffer from diabetes. A 1% increase in HgA1C Is associated with 28% increase in the risk of PA (Paraskevas, 2011). Because of the decreased sensation associated with poor circulation around the feet in diabetes, claudication might be a lacking symptom and initial presentation of PAD might be with ulceration, infection, or gangrene.
Hypertension is a risk factor for PAD, although, to a weaker extent than diabetes and smoking. The Framingham Heart Study showed an increased risk of IC by 2.5 fold for men and fourfold for women with hypertension, with a proportional risk with the severity of hypertension (Murabito et al., 1997).
Dyslipidemia is a risk factor for PAD, highly related to its contribution to atherosclerosis. The ratio of total cholesterol to HDL was found to be the best predictor of PAD in the Framingham study. The Study also found that cholesterol levels over 270 had a twofold increase of frequency of IC (Murabito et al., 1997). Additionally, focus should be of total cholesterol, LDL, triglycerides, and lipoprotein (a) in PAD patients.
Inflammatory risk markers
Elevated levels of C-reactive protein (CRP), were found to have a 2.5 fold increase in PAD development in the Physicians Health Study (Hirsch et al., 2006). CRP, an inflammation risk marker, has become a valuable measurement of risk in healthy individuals (Suominen, 2008). Currently, other inflammatory ¿½biomarkers¿½ are being studied for their ability to increase recognition for disease and thereby improve care (Cooke & Wilson, 2010). A recent prospective cohort study of 1,000 ambulatory elderly Japanese subjects for 8 years revealed that B2M, cystatin-C, and CRP were all independent mortality predictors, the most informative being B2M (ShinkaI, 2008).
Hyperviscosity and hypercoagulable states
Elevated fibrinogen levels, a known risk factor for thrombosis, can cause an alteration in microcirculation, and in turn, worsen claudication symptoms of PAD. Hyperviscosity and hypercoagulability are considered to be risk factors for and indicate poor prognosis of PAD (Norgren, 2007).
Evidence shows a direct correlation of high homocysteine levels and atherosclerosis, leading many to believe that elevated levels directly increase the risk for developing PAD. Approximately 30 to 40% of patients with PAD have high levels of homocysteine (Hirsch et al., 2006). There has been recent speculation, however, on whether elevated homocysteine levels actually relate to primary cause or possibly are just a major mediator of PAD, as a marker of endothelial or systemic oxidative stress (Hoffman, 2011).
6. Clinical Manifestations
A complete cardiovascular and peripheral vascular history is indicated if any risk factors or potential symptoms of PAD are present, including atypical symptoms that may limit walking ability. Family history of PAD, CVD, CAD, CKD and aneurisms should be included. Clinical manifestations differ in relation to their classification.
PAD can be very difficult to diagnose clinically since approximately half of all patients are asymptomatic (Hirsch, 2006). If asymptomatic, the patient will have no symptoms of claudication, no symptoms of ischemic pain, and no limitation in walking distance. Past medical history, tobacco use, family history, and physical exam findings are key for further workup and diagnosis in these patients. Other vascular symptoms that, if positive, could indicate the need for further PAD workup are: erectile dysfunction, post-prandial abdominal pain with associated anorexia or weight loss, upper extremity exertional pain, symptoms suggestive of angina, or transient or permanent neurological symptoms.
Intermittent claudication is considered the hallmark symptom of PAD. Patients may describe leg pain that is aching, numbing, heavy in nature, fatiguing or cramping. It typically affects the muscles of the calves and feet, below the origin of arterial compromise. It can also occur in the buttock or thigh, indicating arterial compromise in the femoral artery. Although intermittent claudication is the classic symptom of PAD, it is actually only present in 10% of patients with the disease (Domino, 2012). Patients with co-morbidities that prevent sufficient activity to produce limb symptoms (i.e. congestive heart failure, severe pulmonary disease, musculoskeletal disease, deconditioned) make it difficult to assess for claudication.
Atypical leg pain is a much more common manifestation of PAD, affecting 40-50% of patients (Domino, 2012). Often, atypical pain is a result of comorbidities, physical inactivity, or alterations in pain perception. It might present similarly to IC, but not be severe enough to stop walking and rest. Alternatively, it might not resolve after 10 minutes of rest or might be present both with exertion and rest (Mohler, 2010). Hirsch explained atypical leg pain as any discomfort in the legs or heels that is present at rest or during exercise and may not be confined to the muscle. He also notes the higher prevalence, like in CVD, of atypical PAD symptoms in women (2012). ¿½
The Edinburgh Claudication Questionnaire (see table 2) is an additional tool that has been shown to be 91% specific and 99% sensitive for diagnosing intermittent claudication in symptomatic patients. It is composed of a series of six questions and a pain diagram that can be self-administered by the patient (Sontheimer, 2006).
Critical limb ischemia
CLI, characterized by persistent rest-pain and tissue loss, affects 1-2% of patients with PAD (Hirsch et al., 2005). Rest pain related to critical limb ischemia is typically severe in nature and might only be relieved by opiates. It often is worse when the leg is supine and might improve by having the leg dependent. It often manifests as nocturnal burning pain, located on the arch of the foot. Inquiry of sleeping position might aid in diagnosis, as many patients will sleep in a chair or with their leg hanging over the bed to prevent, lessen or alleviate pain.
Non-healing or slowly healing wounds below the level of the knee are also associated with critical limb ischemia. The patient might report a purple or black color change in the toes or foot, which can be a sign of gangrene or necrosis. Oftentimes, this will be seen on the digits or the heel, especially if the patient is bedridden. Local trauma, poor fitting shoes, or local heat can also cause ulceration (Norgren et al., 2007).
Acute limb ischemia
Acute limb ischemia is a medical emergency. The patient will likely present with sudden onset of severe leg pain, possibly accompanied by extremity weakness, numbness, coolness, and pallor. Severe cases may cause loss of motor function (Hallett, 2008). History taking should include the symptoms and severity of the current presentation (present illness) as well as background information pertaining to etiology, differential diagnosis and concurrent disease (Norgren et al., 2007).
7. Physical Exam
The physical exam for suspected or known PAD includes a focused cardiovascular and complete peripheral vascular system exam. The ACC/AHA guidelines suggest the following physical exam elements be completed in all patients with suspected or known PAD:
¿½Palpate the carotid pulses and note carotid upstroke and amplitude. Auscultate the carotids, abdomen and flank for bruits. Palpate the abdomen and note the presence of the aortic pulsation and its maximal diameter. Palpate the pulses at the brachial, radial, ulnar, femoral, popliteal, dorsalis pedis, and posterior tibial sites. Perform Allen¿½s test when knowledge of hand perfusion is needed. Auscultate both femoral arteries for the presence of bruits. Pulse intensity should be assessed and should be recorded numerically as follows: 0, absent; 1, diminished; 2, normal; and 3, bounding. The shoes and socks should always be removed and the feet inspected for color, temperature, and integrity of the skin and intertriginous areas¿½ (2006).
It is also important to measure the blood pressure in both arms because upper extremity PAD, specifically subclavian steal, can present with differences of 15 mm Hg or more systolically between arms (Mohler, 2007). There is a 96% specificity of PAD and 93% for CVD when seen (Clark et al., 2012).
Some ?ndings suggestive of severe PAD, including distal hair loss, trophic skin changes, and hypertrophic nails, should be sought and recorded. The most reliable physical findings for PAD include absent or diminished pedal pulses, the presence of a femoral artery bruit, skin color abnormalities, and coolness of the skin (Hirsch, et al., 2006).
Patients with ALI may initially present with a combination of ?ve symptoms, known as the ¿½¿½5 Ps¿½¿½: pain, pulselessness, pallor, paresthesia, or paralysis. Additional findings indicating advanced ALI are muscle rigor, tenderness, or ?ndings of pain with passive movement (Norgren, 2007).
The aim of the laboratory assessment in patients with asymptomatic or symptomatic disease is to detect major risk factors of CVD. There are no current guidelines for routine or diagnostic lab work in these patients. CBC with platelet count, Hg A1C, CRP, fibrinogen, fasting lipid profile, serum creatinine, and urinalysis for glucosuria and proteinuria might all be helpful when considering risk factors or coexisting diagnosis (Sontheimer, 2006).
In patients with ALI, electrocardiogram, standard chemistry, CBC, prothrombin time, partial thromboplastin time and creatinine phosphokinase level should be obtained. If hypercoagulable state is suspected, additional studies seeking anticardiolipin antibodies, elevated homocysteine concentration and antibody to platelet factor IV should be ordered (Norgren, 2007).
8. Differential diagnosis
PAD has a diversity of causes beyond atherosclerosis, including thromboembolic, in?ammatory, or aneurysmal disease; by trauma, adventitial cysts, or entrapment syndromes; or by congenital abnormalities. Establishment of an accurate diagnosis is necessary if individual patients are to receive ideal pharmacological, endovascular, surgical, or rehabilitative interventions (Hersch, 2006). See Table 3 for common differential diagnoses for IC.
Differential diagnosis for ALI has three primary entities. The first, CHF, in the presence PAD, can present similarly when severe low output states lead to lack of pulse and to classic findings of pain, pallor, paresthesia, and paralysis. Although a similar presentation to ALI, angiography will not show an occlusion. Second, deep vein thrombosis can present as a large, swollen, and painful leg. The leg might appear blue due to venous infarction, but without paleness. Pulses may be absent secondary to thrombotic occlusion. Lastly, acute spinal cord compression can imitate CLI, with pain, paresthesia, and paralysis; however, normal skin color and pulses will be present (Sontheimer, 2006).
9. Diagnostic evaluations
Noninvasive testing can help detect early PAD and, with appropriate intervention, help prevent progression to critical leg ischemia and amputation. In addition, it predicts future ischemic cardiac and cerebral events and thus can be used to detect persons who would benefit from medical therapy.
A standard part of the initial PAD evaluation is the measurement of arterial pressures, by means of the ABI. Patients who have a pertinent history or physical examination suggestive of PAD should proceed to objective testing including an ABI. The test is done with the use of a sphygmomanometer cuff placed just above the ankle and a doppler to measure the systolic pressure of the posterior tibial or dorsalis pedis arteries. The systolic blood pressure is then placed in a ratio equation comparing the systolic pressure of the arm on the same side. Current guidelines recommend using the ABI to establish the diagnosis of PAD in patients with suspected disease, defined as individuals with one or more of the following: exertional leg symptoms, nonhealing wounds, age 65 years and older, or 50 years and older with a history of diabetes or smoking, or less than 50 with DM and another risk factor (Rooke, et al., 2011). The normal range of ABI is 1.00 to 1.40 and ABI values of 0.91 to 0.99 are considered borderline. ABI from 0.71 to 0.9 indicates mild PAD and 0.41 to 0.7 indicates moderate disease. An ABI of less than 0.4 is indicative of severe ischemia. If ABI is found greater than 1.4, calcified vessels should be suspected and additional diagnostic studies are warranted (Domino, 2012). ABIs with readings this high are commonly seen in patients with diabetes, renal insufficiency, or other diseases causing vascular calcification.
In patients with pertinent claudication but normal ABI results, additional exercise testing with ABI measurements can be ordered. The procedure requires an initial measurement of the ABI at rest. The patient might be asked to walk (typically on a treadmill at 3.2 km/h (2 mph, 10%¿½12% grade) until their claudication pain is reproduced (a maximum of 5 minutes), after which the ABI is again measured. A decrease in ABI of 15%¿½20% would be diagnostic of PAD. Walking exercises in the hallway or in a stairwell can be used as an alternative to a treadmill if unavailable (Norgren, 2007).
The ABI is a noninvasive, inexpensive, office-based test that can reliably be performed by most trained healthcare personnel. The ABI is an accurate and diagnostic measure for PAD, with a sensitivity of 95% and specificity of 100% in detecting PAD with an ABI less than 0.9. This ABI risk prediction for PAD has recently been demonstrated to be independently valuable and its use would add incrementally to the Framingham risk score .(Fowkes,¿½2008). The test can confirm the diagnosis of PAD, even in patients who are asymptomatic, and is useful in the differential diagnoses of leg symptoms to identify vascular etiology (Hirsch et al., 2006). However, ABI is intended for office-based and vascular laboratory diagnostic use and is not intended to serve as a population screening tool. The use of ABI measurement should be used as diagnostic workup of suspected disease or in the presence of known risk factors, not for general screening of asymptomatic patients. This recommendation was based on the fact that the treatment of asymptomatic PAD, beyond standard cardiovascular assessment and treatment, does not improve major health outcomes (Screening for Vascular Disease, 2009).
Toe Brachial Index (TBI).
Similar to the ABI, the TBI is a quick and cost effective way to establish the diagnosis of PAD. With the use of smaller cuffs and careful technique to preserve accuracy, measurement of digital perfusion can be established when small-vessel arterial occlusive disease is present. For patients with non-compressible posterior tibial or dorsalis pedis arteries, the TBI is a useful alternative to the ABI (Norgren, 2007).
Segmental leg pressures.
The extent and location of PAD can be further defined with the measurement of segmental leg pressures (SLP). Obtained the same way as the ABI, segmental leg pressures differ in that they are done at the level of the thigh and calf. Similar limitations with non-compressible pedal arteries can potentially altar accuracy and alternative testing should be done.
Pulse volume recordings.
Also useful for establishing PAD diagnosis, pulse-volume recordings (PVR) measure arterial perfusion, even in patients with non-compressible vessels. PVR is also useful to monitor limb perfusion after revascularization procedures. Limitations include a decrease in accuracy in more distal segments, abnormal readings in patients with low cardiac stroke volume, and providing only qualitative, not quantitative, measurement of perfusion. Both SLP and PVR provide more of an objective assessment of the location and presence of PAD¿½both alone are 85% accurate in detecting significant stenosis compared to angiography, but when used together, a 97% diagnostic accuracy has been reported (Norgren et al., 2007).
Doppler velocity waveform analysis.
Arterial velocity waveform analysis is a useful study that uses a continuous-wave doppler at multiple sites in the peripheral circulation. This test visualizes the arteries with sound waves and measures the blood flow in an artery to indicate the presence of a blockage.¿½ Healthy peripheral vessels will have a triphasic pattern and progress to a biphasic and, ultimately, monophasic appearance in patients with significant PAD. When assessed over the posterior tibial artery, a reduced or absent forward flow velocity was highly accurate for detecting PAD. Measurements are useful to provide an accurate assessment of lower extremity PAD location and severity, to follow lower extremity PAD progression, and to provide quantitative follow-up after revascularization procedures. While the test is operator-dependent, it provides another diagnostic method in patients with noncompressible tibial arteries (Norgren et al., 2007).
Duplex ultrasound (DUS).
Arterial duplex ultrasonographic examination is also used to diagnose PAD, but is primarily used to investigate anatomic location and degree of stenosis in pre-diagnosed PAD. It can delineate between stenotic and occlusive lesions above the level of the knee, which makes it useful in assessing the need of endovascular or surgical intervention as well as selecting potential sites of anastomosis. Current guidelines recommend its use for routine surveillance after femoral-popliteal or femoral-tibial bypass (Rooke et al., 2011). Duplex ultrasonography combines the waveform analysis and velocities of doppler imaging. The sensitivity and specificity of the diagnosis of stenosis greater than 50% of the vessel diameter from the iliac to the popliteal arteries are each approximately 90-95% (Rybicki, 2009).
Imaging is indicated for patients in whom the decision has been made to proceed with revascularization when a suitable lesion is demonstrated.
Magnetic resonance angiography (MRA).
Although not the gold standard for PAD imaging, MRA has become the first line of pre-surgical imaging in many centers across the country. The sensitivity and specificity for detection of stenosis when greater than 50% in diameter is 90% to 100%. It is more accurate in detecting significant stenosis for pre-operative planning than DUS. The major limitation of using MRA is the risk of nephrogenic systemic fibrosis (NSF), related to its use of gadolinium, and alternative study is indicated in patients with abnormal renal function (Rybicki, 2009). MRAs are contraindicated in patients that have any form of metal inside their body: pacemakers, defibrillators, intracranial metallic stents, clips, coils, or other devices.
Computed tomographic angiography (CTA).
CTA of the extremities may be considered to diagnose the presence of and anatomical location ofsignificant stenosis in patients with PAD and is used primarily as a substitute for MRA in the presence of contraindications. Although the risk is less than of gadolinium, contrast materials must be used, and precautions should still be considered in patients with abnormal kidney function. Like MRA, sensitivity and specificity for detection of stenosis greater than 50% in diameter is 90% to 100%. Its major limitation is visualization in the presence of significant calcified atheromatous disease, and testing should be avoided in these patients (Rybicki, 2009).
Invasive diagnostic testing
Contrast angiography is the gold standard and definitive method of anatomical evaluation under some circumstances (i.e. acute limb ischemia), because it offers the benefit simultaneous intervention, if needed. This test is invasive and it carries risk of bleeding, infection, embolism, contrast allergy, and contrast nephropathy. This method provides the most detailed information about the arterial anatomy and is recommended for evaluation of patients when revascularization is contemplated, to help develop an individualized diagnostic plan, select access sites, identify significant lesions, and to ensure the need for invasive evaluation. Noninvasive imaging modalities, such as MRA, CTA, and color flow duplex imaging, may be used in advance of invasive therapy. Follow-up evaluation is necessary 2 weeks after contrast angiography to evaluate renal function, presence of insertion site injury, and to detect any possible delayed adverse effects, such as atheroembolism. (Rybicki, 2009).
10. Medical management
The medical management goals of claudication are: risk factor modification, a supervised exercise program, the use of antiplatelet drugs, and possibly, medication for symptom improvement.
Risk factor modification
Since smoking is one of the two most jeopardizing, modifiable risk factors of PAD, it is imperative to address this issue with patients. In 2011, the ACC/AHA updated the guideline, advising practitioners to ask patients who are current or former smokers about the current status of their tobacco use at every visit. Patients with current use should be assisted with counseling and developing a quit plan that may include pharmacotherapy and/or referral to a smoking cessation program. Individuals with preexisting PAD who use tobacco should be advised by each of their clinicians to stop as well as being offered behavioral and pharmacological treatment. In the absence of contraindication or other compelling clinical indication, one or more of the following pharmacological therapies should be offered: varenicline, bupropion, and nicotine replacement therapy (Rooke et al., 2011).
It is well known that better glycemic control can help prevent microvascular complications such as retinopathy and neuropathy. Unfortunately, no studies have correlated the effects of glycemic control in patients with PAD. Current PAD guidelines coincide with that of the current American Diabetes Association guidelines, which recommend a HbA1c <7.0%. Metformin is an effective first-line pharmacotherapy and can be useful if not contraindicated (Rooke, et al., 2011).
Current cholesterol goals for PAD are based on the ATP III guidelines: 1) LDL-C goal of <100 mg/dL, 2) LDL-C goal of <70 mg/dL is reasonable for very high risk patients, and 3) if triglycerides are ?200 mg/dL, non¿½HDL-C¿½¿½should be <130 mg/dL, whereas non¿½HDL-C <100 mg/dL for very high risk patients is reasonable (Smith, et al., 2011). In the presence of PAD, the first line of therapy for reducing a patient¿½s cholesterol is not only therapeutic lifestyle changes (dietary modification and increased exercise), but also the initiation of a HMG CoA reductase inhibitor (statin therapy). Statins are important drugs to reduce cardiovascular events in patients with documented PAD and have been shown to reduce claudication and increase walking distance by 24% at 6 months and 42% at 1 year compared with placebo (Shammas, 2007). Simvastatin (20¿½40 mg/d) has been shown to reduce the incidence of new intermittent claudication from 3.6¿½2.3% in patients with asymptomatic PAD (Domino, 2012).¿½For patients who are intolerant of statins, or if treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not achieve the goal selected for a patient, a secondary LDL-C¿½lowering drug therapy of a bile acid sequestrant or niacin should be initiated (Smith, et al., 2011).
Obesity has been shown to worsen the symptoms of PAD. It decreases the time to claudication and increases the time needed for recovery after exercise. In order to manage patients who are overweight or obese, a comprehensive plan should be implemented including structured caloric intake, balanced lifestyle physical activity and exercise, and a formal behavioral program to maintain a body mass index (BMI) between 18.5 and 24.9. Target waist circumference in women is less than 35 inches and in men, less than 40 (Smith et al., 2011).
Blood pressure control.
Patients with hypertension and PAD should be maintained on an antihypertensive medication to reduce the risk of MI, stroke, CHF, and cardiovascular death. Current guidelines state that the BP goal for these patients is 140/90. For those PAD patients with coexisting DM or CKD, the BP goal should be 130/80. Essentially, all forms of antihypertensives are safe to use in patients with PAD (Hankey et al., 2006). Thiazide diuretics and angiotensin converting-enzyme inhibitors (ACE inhibitors) should be used as first line treatment. ACE inhibitors may increase the perfusion function and walking distance in patients with PAD as well as reduce the risk of adverse cardiovascular events. In the HOPE clinical trial, patients with PAD who had randomly been assigned to receive ramipril experienced a 25% reduction in the number of major cardiovascular events. In addition, the mean blood pressure of the patients with PAD in this study was 143/79, which suggests that ACEIs could even be beneficial in normotensive patients (O¿½stergren et al.,¿½2004). Although beta blockers were once believed to worsen intermittent claudication, a recent Cochrane review of 6 randomized studies comparing beta-blocker and placebo showed no statistically significant worsening effect of beta-blockers on maximum walking distance, claudication distance, calf blood flow or skin temperature (Paravastu et al., 2008).
Supervised exercise program
Supervised exercise therapy should be the cornerstone of the initial treatment for patients with IC (Norgren et al., 2007). Treadmill walking is the most superior form of exercise therapy in PAD (Hamburg & Balady,¿½2011). Research has showed that an effective PAD exercise program should be a minimum of 30-45 minutes (including rest periods), in sessions performed at least 3 times a week, for a minimum of 12 weeks (Hirsch et al. 2006). The patient should walk on a treadmill at a given pace at which the patient experiences the onset of claudication. The patient should then continue walking until the ischemic leg pain is scored 6-8 on a scale of 10. The exercise is then stopped until the pain completely subsides. The exercise is then resumed at similar intensity, and the pattern of walk, pain, rest continues. The pace can be intensified when the patient is able to walk for 8 minute bouts without stopping for leg pain (Bronas et al., 2009).
Supervised exercise programs appear to deliver a greater improvement in functional measures compared to unsupervised training, likely related to¿½better patient adherence and greater intensity of treadmill exercise compared to normal walking. Unfortunately, many patients are without insurance or their insurance company will not cover exercise therapy, and in this case, an unsupervised program might be the only option. Provider education and motivation of an outlined program can be helpful in patient compliance. The patient might also benefit from including a family member or friend in their exercise regimen to help with adherence, intensity, and motivation.
Antiplatelet therapy is indicated to reduce the risk of stroke, MI, and other causes of vascular death in individuals with symptomatic PAD. Aspirin (81 to 325 mg per day) is an effective and safe first line antiplatelet therapy for these patients. Clopidogrel (75 mg per day) is recommended as a safe and effective alternative to aspirin. These medications can also be combined to reduce the risk of cardiovascular events in patients who are not at increased risk of bleeding and who are at high-risk level. Although the efficacy is not well-established, guidelines suggest the use of antiplatelet therapy in asymptomatic individuals with an ABI less than or equal to 0.9, as it can be useful to reduce the risk of vascular complications. The benefits of these medications in patients with asymptomatic PAD are not well established (Rooke et al., 2011). Ticlopidine, an inhibitor of platelet aggregation, has been found to have modest increase in walking distance in patients with IC as well as reducing risk of MI, stroke or death in one third of patients with PAD. Unfortunately, it is rarely used because of a substantial risk of leukopenia and thrombocytopenia and has been replaced by clopidogrel (Hankey et al., 2006). Coumadin has no proven indication in the management of PAD (Rooke, 2011). The provider should educate patients on all potential serious side effects of antiplatelet use that require medical assistance, including coughing that produces blood, numbness, chest pain, pale skin, uncontrolled bleeding, and or easy bruising.
Medication for symptom management
Cilostazol is a phosphodiesterase inhibitor with vasodilating and antiplatelet activity. It is recommended as an effective first choice therapy to increase walking distance and improve claudication symptoms in patients with PAD. ¿½In addition to benefiting both symptoms and quality of life, cilostazol appears to have beneficial effects on arterial compliance (Stevens, 2010). The medication, given 100 mg po bid, is contraindicated in patients CHF or EF<40 40. Side effects included headache, diarrhea, and palpitations (Saljoughian, 2012).
Pentoxifylline is a methylxanthine derivative that also has antiplatelet, anti-inflammatory, and hemorheologic effects. The FDA approved it in 1984 for the treatment of IC; however, two meta-analyses and two systematic reviews have proven its effect on walking capacity improvement to be small, if any. The ACC/AHA guidelines conclude pentoxifylline (400 mg po tid) may be considered a second-line drug to¿½cilostazol for improved walking distance in IC. Gastrointestinal upset is the most common side effect.
Ginko biloba has shown to have mild benefit in patients with IC in several trials. The mechanism by which it works is unclear, but may be related to its antioxidant effect, inhibition of vascular injury, and antithrombotic effects (Mohler, 2012). Currently, the ACC/AHA guidelines do not recommend Ginko biloba and concluded the benefit has¿½not¿½been established for the treatment of claudication (Hersch, 2006).
11. Surgical management
Surgical interventions are indicated for individuals with PAD whose claudication symptoms have significant vocational or lifestyle limiting functional disability and have a reasonable likelihood of symptomatic improvement. These patients should have already failed to benefit from exercise and pharmacological therapy and their risk-benefit ratio for intervention must be favorable. The goals of revascularization are: 1) to relieve the disabling claudication or rest ischemic pain, and 2) to limit the degree of amputation or minimize tissue loss. The need to intervene is more urgent in patients with ALI.
Endovascular procedures for treatment of PAD include balloon angioplasty, stenting, stent grafts and plaque debulking procedures. Thrombolysis and percutaneous thrombectomy are additional endovascular therapies that are typically reserved for acute limb ischemia.
Endovascular procedures have become the preferred method over the past decade for initial revascularization in a patient with PAD because of their lower complication rates, lack of general anesthesia, being less invasive, having a shorter recovery, and the fact that they do not preclude further surgery, if needed. Follow-up clinical evaluations after revascularization should evaluate progression or return of claudication, evaluation of pulses, and the measurement of ABI, both at rest and after exercise. Complications include thrombosis or embolism distal to site, intimal dissection, and complications related to heparin (Yang, 2012).
Surgical procedures for the management of PAD include autogenous or synthetic bypass, endarterectomy, or an intra-operative hybrid procedure. Guidelines from multiple societies agree that the use of surgery for initial management of patients with PAD should be reserved for when arterial anatomy is not favorable for a percutaneous approach (Neschis & Golden, 2012). In the setting of failed medical therapy and previous attempts of revascularization, given that there are no contraindications and in the presence of favorable anatomy, surgical revascularization is recommended (Noragren et al., 2007). Like any procedure requiring intubation and anesthesia, both cardiac evaluation and pre-op clearance are needed prior to surgery. In addition to the follow-up care involved in endovascular procedures, duplex imaging is indicated perioperatively and postoperatively if bypass method was used. Postoperatively, they should be re-evaluated at 6 weeks postop, then every 3 months for 2 years, and at six-month intervals then after. Studies have shown that with routine monitoring, long-term patency rates of 82-93% can be achieved versus 30-50% long-term patency in the unmonitored (Neschis & Golden, 2012).
In some situations, amputation may be the procedure of choice for CLI or ACI. In the presence of infectious gangrene, extensive necrosis, non-ambulatory patients, or when there is unrelenting rest pain unrelieved by other measures, amputation should be considered. Amputation is the last surgical step for treatment of irreversible limb ischemia, with potential ambulatory recovery with prosthesis and rehabilitation. In the case of the nonsurgical patient, supportive measures with adequate analgesia may be considered the best option.
Lumbar sympathectomy is controversial treatment that may be effective for severe ischemic pain. Chemical sympathetic blocks are injected lateral to the spinal cord and could potentially give pain relief and mild vasodilation (Neschis & Golden, 2012).
Therapeutic angiogenesis involves the administration of vascular growth factors and has emerged as a possible alternative treatment for PAD. Autologous bone marrow mononuclear cells implantation in PAD patients with CLI may improve lower limb ischemic symptoms according to preliminary evidence; however, further data from larger studies is required before any solid conclusions can be reached (Fadini et al., 2010).
12. Emergency management
ALI is a medical emergency whose diagnosis is clinical. Urgent history and physical examination as well as either ABI or duplex ultrasound should be performed. Urgent antiplatelet agents such as aspirin or Plavix should be given. Limb viability should be determined and in the presence of nerve damage, sensory loss, or tissue loss, amputation will likely be required. Immediate vascular consult is required and angiography should be done to confirm location of occlusion, identify collateral blood flow, and guide therapy. Treatment options include surgical or Catheter-based embolectomy, thrombolysis, or bypass surgery.¿½ In patients with acute arterial occlusions of less than 2 weeks and in whom sensory and motor function remains intact, thrombolytic therapy is the most effective treatment (Hirsh, 2006). Even with immediate treatment upon presentation, 20 to 30% of patients with acute peripheral arterial occlusion will have to undergo amputation (Hallett, 2008).
13. Patient education, disease maintenance, and prevention
According to Dr. Hirsch, 95% of PAD care can be offered in a motivated internist¿½s office where risk reduction, symptom treatment and avoidance of CLI can be achieved and vascular referral is only needed when revascularization is considered (2006). Patient maintenance entails follow-up visits annually for asymptomatic patients, and every 4-6 months for those who are symptomatic. Pulse examination should be done as well as ABI when there is concern of considerable disease progression (Stephens, 2010).
All patients should be counseled regarding the need for lifestyle modification including weight control, increased physical activity, alcohol moderation, sodium reduction, and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products. In the presence of comorbidities, the patient should be educated regarding the importance of smoking cessation, blood pressure control, diabetes control, and cholesterol control. In addition to a podiatry consult, diabetic patients should also have thorough foot care education on foot inspection and skin cleansing. Use of topical moisturizing creams should be encouraged and skin lesions and ulcerations should be addressed urgently. Advice about avoiding the cold, keeping legs below heart level (especially at night), and avoiding vasoconstrictive medications (e.g., pseudoephedrine) should also be given.
Some recreational drugs (e.g., cocaine, methamphetamine) also may have a deleterious effect on peripheral arterial tone and should be counseled against.
Screening for depression should also be considered, as there is a greater risk of depression in PAD and a greater risk for PAD complications if present (Grenon, 2012).
Referral to a vascular specialist is warranted under several circumstances. In the presence of iliac artery disease, symptomatically represented by hip, thigh or buttock claudication and reduced femoral pulses, referral is indicated for possible stenting. In patients with normal femoral pulses and abnormal popliteal, dorsalis pedis or posterior tibial pulses, referral is needed only in patients who do not respond to maximal medical therapy, at which referral is indicated for further imaging. Additionally, if ABI is <0.5, the patient needs immediate referral to a vascular surgeon to determine whether surgical intervention is required to improve vascular supply to the periphery (Olin, 2010).
Patients with PAD have increased risk for MI regardless of whether or not they have symptoms. There is a 20%-60% increased risk for MI and a 40% increased risk of stroke. (Hirsch, 2006). If claudication exists, 5-10% will progresses to CLI ("Treatment Strategies for Patients With Peripheral Artery Disease¿½,¿½2012). For the most part, claudication symptoms remain stable and do not worsen rapidly. There are two clinical risk factors for rapid worsening: 1) significantly reduced ABI and 1) DM, which both increase the risk for CLI (Hirsch, 2006).¿½In the Framingham study, only 1.6% of patients with claudication reached the amputation stage after 8.3 years of follow-up (Murabito et al., 1999). Predicted mortality rates for patients with claudication at 5, 10, and 15 years of follow-up are approximately 30%, 50%, and 70%, respectively (Stevens, 2010). With critical limb ischemia, the one year outcome for both mortality and amputation is approximately 25% each, with about 50% of patients alive with 2 limbs (Hirsch et al.,¿½2006). With ALI, the long-term prognosis for both the patient and the extremity depends upon the promptness and completeness of revascularization and whether it is done prior to onset of nerve and permanent tissue damage. Patient prognosis two years following a below-knee amputation is: 30% mortality; 15% receive an above-knee amputation; 15% receive a contralateral amputation; and only 40% have full mobility (Tendera et al., 2011).